問卷

TPIDB > Search Result

Search Result

篩選

List

53Cases

2025-09-30 - 2027-06-30

Phase II

Active
A phase 2, randomized, double-blind, placebo-controlled proof-of-concept trial was conducted to evaluate the efficacy and safety of EI-001 in patients with non-segmented vitiligo.
  • Condition/Disease

    • Percentage change of F-VASI relative to baseline in week 24

  • Test Drug

    EI-001

Participate Sites
2Sites

Recruiting2Sites

2024-02-01 - 2026-07-27

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2023-04-01 - 2031-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2025-03-01 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2024-09-15 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-05-31 - 2027-05-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-11-01 - 2028-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-09-01 - 2026-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-01-09 - 2026-02-28

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2023-10-10 - 2027-07-14

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites